サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467598

がんモノクローナル抗体の世界市場：抗体タイプ別、薬剤タイプ別、用途別、エンドユーザー別、地域別（2024～2032年）

Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Others), Application, End-User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
がんモノクローナル抗体の世界市場：抗体タイプ別、薬剤タイプ別、用途別、エンドユーザー別、地域別（2024～2032年）
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんモノクローナル抗体の市場規模は、2023年に466億米ドルに達し、2024～2032年にかけてCAGR 3.6%で成長し、2032年までに646億米ドルに達すると予測されています。

がんモノクローナル抗体とは、がん細胞に対する免疫系の攻撃を模倣するように設計された、実験室で作製された分子を指します。がん細胞の表面に存在する抗原に結合し、細胞膜の破壊を誘発するフラグを立て、細胞増殖や免疫系阻害をブロックすることができます。また、治療用の放射線をがん細胞に直接照射して、がん細胞を中和または破壊することもできます。最も一般的に使用されているモノクローナル抗体には、マウス抗体、キメラ抗体、ヒト化抗体などがあり、血液、肝臓、脳、乳房などのがん治療に使用されています。

世界中でがんの有病率が増加していることが、市場の成長を促進する主な要因の一つです。化学療法など従来から使用されている非標的療法と比較すると、モノクローナル抗体は患者の体への副作用が少なく、自己免疫疾患や炎症性疾患の治療にも使用できます。さらに、コスト効率の高いバイオシミラーモノクローナル抗体が開業医や腫瘍医に広く採用されていることも、市場の成長を後押ししています。遺伝子配列の決定と標的遺伝子の選択における技術の進歩により、これらの抗体は医薬品と同様の特性を持つように改変することができます。抗体は同じ効能を持ちながら、オリジナルの医薬品よりも低価格で入手できるため、治療の費用対効果を高めることができます。その他の要因としては、個別化医薬品への嗜好の高まり、広範な研究開発活動、ヘルスケアインフラの大幅な改善などがあり、市場をさらに牽引すると予測されます。

本レポートで扱う主な質問

  • 世界のがんモノクローナル抗体市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 主要な地域市場は？
  • COVID-19が世界のがんモノクローナル抗体市場に与えた影響は？
  • 抗体タイプ別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 用途別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のがんモノクローナル抗体市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データ情報源
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 がんモノクローナル抗体の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：抗体タイプ別

  • マウス抗体
  • キメラ抗体
  • ヒト化抗体
  • その他

第7章 市場内訳：薬剤タイプ別

  • ベバシズマブ（アバスチン）
  • リツキシマブ（リツキサン）
  • トラスツズマブ（ハーセプチン）
  • セツキシマブ（アービタックス）
  • パニツムマブ（ベクティビックス）
  • その他

第8章 市場内訳：用途別

  • 乳がん
  • 血液がん
  • 肝臓がん
  • 脳腫瘍
  • 大腸がん
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院・クリニック
  • 薬局
  • 調査研究所
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Roche Holding AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc.
    • Seattle Genetics Inc.
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2023
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2023
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2023
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US$), 2024-2032
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players
目次
Product Code: SR112024A1955

The global cancer monoclonal antibodies market size reached US$ 46.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 64.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on antibody type, medication type, end-user and application.

Breakup by Antibody Type:

Murine Antibodies

Chimeric Antibodies

Humanized Antibodies

Others

Breakup by Medication Type:

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbitux)

Panitumumab (Vectibix)

Others

Breakup by Application:

Breast Cancer

Blood Cancer

Liver Cancer

Brain Cancer

Colorectal Cancer

Others

Breakup by End-User:

Hospitals and Clinics

Pharmacies

Research Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Roche Holding AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AbbVie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Genmab A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 GlaxoSmithKline Plc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Bristol-Myers Squibb Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Spectrum Pharmaceuticals Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Seattle Genetics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Pfizer Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis